On this page:
IgA nephropathy is an autoimmune disease that occurs when clumps of antibodies are deposited in your kidneys, causing inflammation and kidney damage. Clumps of immunoglobulin A (IgA) and other antibodies damage the glomeruli, tiny blood vessels in your kidneys that filter blood, causing your kidneys to leak blood and protein into your urine. The damage may also lead to the scarring of the nephrons, the filtering units where the glomeruli are located.
IgA nephropathy is also known as Berger’s disease.
IgA nephropathy is a common kidney disease, and an important cause of chronic kidney disease and kidney failure.1 About 1 in 10 kidney biopsies in the United States show IgA nephropathy.2
IgA nephropathy is more common in people who1–3
Complications of IgA nephropathy can include3
Symptoms can vary and may not appear for years or even decades. Common signs and symptoms include
These symptoms are common across diseases and do not, by themselves, suggest that you have IgA nephropathy.
The cause of IgA nephropathy is unknown, but research suggests that genes and the environment may play a role.2 In some people, the first signs or symptoms of the disease may become noticeable after a cold, sore throat, or other respiratory infection.
Your health care professional will conduct a physical exam, review your symptoms and family history, and order urine and blood tests to find out how well your kidneys are working.
To make a diagnosis, your health care professional will order a kidney biopsy.1 The biopsy can
Health care professionals—in most cases, kidney experts called nephrologists—treat IgA nephropathy with1, 4
In some cases, your health care professional may also prescribe immunosuppressants, including corticosteroids. But these medicines can cause serious side effects, such as weight gain or a weakened immune system.
Although researchers have not yet found a cure for IgA nephropathy, treatment can help prevent or delay damage to your kidneys. New treatments are under development, and several are being evaluated in clinical trials.
In many cases, IgA nephropathy does not get worse over time. But if the disease progresses to kidney failure, you may need a kidney transplant or blood-filtering treatments called dialysis.
You can’t prevent IgA nephropathy. If you have a family history of the disease, ask your health care professional how to keep your kidneys healthy.
Researchers have not found evidence that eating, diet, and nutrition play a role in causing or preventing IgA nephropathy. If you have IgA nephropathy, limiting the amount of salt in your diet may help reduce swelling and lower blood pressure. Your health care professional may suggest other changes to your diet based on your symptoms, lab test results, and personal needs.
NIDDK conducts and supports clinical trials in many diseases and conditions, including kidney diseases. The trials look to find new ways to prevent, detect, or treat disease and improve quality of life.
Clinical trials—and other types of clinical studies —are part of medical research and involve people like you. When you volunteer to take part in a clinical study, you help doctors and researchers learn more about disease and improve health care for people in the future.
Researchers are studying many aspects of IgA nephropathy, such as
Find out if clinical trials are right for you.
Watch a video of NIDDK Director Dr. Griffin P. Rodgers explaining the importance of participating in clinical trials.
You can view a filtered list of clinical studies on IgA nephropathy that are open and recruiting at www.ClinicalTrials.gov. You can expand or narrow the list to include clinical studies from industry, universities, and individuals; however, NIH does not review these studies and cannot ensure they are safe. Always talk with your health care provider before you participate in a clinical study.
This content is provided as a service of the National Institute of Diabetes and Digestive and Kidney Diseases
(NIDDK), part of the National Institutes of Health. NIDDK translates and disseminates research findings to increase knowledge and understanding about health and disease among patients, health professionals, and the public. Content produced by NIDDK is carefully reviewed by NIDDK scientists and other experts.
NIDDK would like to thank:
Bruce A. Julian, M.D., School of Medicine, University of Alabama at Birmingham